BVNKF News and Press, Bavarian Nordic R/I Ord

Regulatory review of the single-dose CHIKV VLP vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older is now underway in both the EU and in the U.S. COPENHAGEN, Denmark, June 26, 2024 – Bavarian Nordic ...

First regulatory submission completed for CHIKV VLP seeking approval of the vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and older Represents first BLA for a chikungunya vaccine for adolescents COPENHAGEN, Denmark, June 17, 2024...

COPENHAGEN, Denmark, May 31, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a freeze-dried formulation of JYNNEOS ® for prevention of ...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-11 08:03:09 ET Bavarian Nordic A/S (BVNKF) Q1 2024 Earnings Conference Call May 08, 2024, 08:00 ET Company Participants Rolf Sorensen - VP, IR & Communications Paul Chaplin - President & CEO Henrik Juuel - EVP & CFO Conference Call Parti...

COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of its CHIKV VLP vaccine candidate for i...

COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS ® , the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS ® by establishing additional pathwa...

2024-03-06 10:46:02 ET Bavarian Nordic A/S (BVNKF) Q4 2023 Earnings Conference Call March 06, 2024 08:00 AM ET Company Participants Rolf Sorensen - Vice President of Investor Relations Paul Chaplin - President & Chief Executive Officer Henrik Juuel - Executiv...

2024-03-06 09:09:35 ET More on Bavarian Nordic A/S Bavarian Nordic pulls plug on cancer vaccine program Historical earnings data for Bavarian Nordic A/S Financial information for Bavarian Nordic A/S Read the full article on Seeking Alpha For further d...

Accelerated assessment allows for a shorter review period with EMA. Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024. COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company...